Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00084266 · ClinicalTrials.gov registry record · Phase 4
Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,225
- Enrollment target
NCT00084266 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 1,225 participants.
The verdict
NCT00084266, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,225 participants
- Enrollment target
Study Summary
To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphylococcus aureus pneumonia which will be treated with either linezolid or vancomycin.
Interventions
- DRUG vancomycin
- DRUG linezolid (Zyvox)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,225 participants |
| Start Date | 2004-10 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00084266
The ClinicalTrials.gov registry entry for NCT00084266 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 1,225 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which vancomycin is the first listed.
NCT00084266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00084266 about?
NCT00084266 is a clinical study titled "Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)". To determine if linezolid is superior to vancomycin in the treatment of nosocomial (acquired in the hospital) pneumonia due to Methicillin Resistant Staphylococcus Aureus (MRSA) in adult subjects. Subjects entered in to the study will have proven healthcare-associated methicillin-resistant Staphyloc...
What is the current status of trial NCT00084266?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,225 participants. The study started on 2004-10. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00084266?
The interventions under investigation include: vancomycin (DRUG), linezolid (Zyvox) (DRUG).
Who is sponsoring clinical trial NCT00084266?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.